Xie Yuchao, Ramachandran Anup, Breckenridge David G, Liles John T, Lebofsky Margitta, Farhood Anwar, Jaeschke Hartmut
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Department of Biology, Gilead Sciences, Inc., Foster City, CA, USA.
Toxicol Appl Pharmacol. 2015 Jul 1;286(1):1-9. doi: 10.1016/j.taap.2015.03.019. Epub 2015 Mar 25.
Metabolic activation and oxidant stress are key events in the pathophysiology of acetaminophen (APAP) hepatotoxicity. The initial mitochondrial oxidative stress triggered by protein adduct formation is amplified by c-jun-N-terminal kinase (JNK), resulting in mitochondrial dysfunction and ultimately cell necrosis. Apoptosis signal-regulating kinase 1 (ASK1) is considered the link between oxidant stress and JNK activation. The objective of the current study was to assess the efficacy and mechanism of action of the small-molecule ASK1 inhibitor GS-459679 in a murine model of APAP hepatotoxicity. APAP (300 mg/kg) caused extensive glutathione depletion, JNK activation and translocation to the mitochondria, oxidant stress and liver injury as indicated by plasma ALT activities and area of necrosis over a 24h observation period. Pretreatment with 30 mg/kg of GS-459679 almost completely prevented JNK activation, oxidant stress and injury without affecting the metabolic activation of APAP. To evaluate the therapeutic potential of GS-459679, mice were treated with APAP and then with the inhibitor. Given 1.5h after APAP, GS-459679 was still protective, which was paralleled by reduced JNK activation and p-JNK translocation to mitochondria. However, GS-459679 treatment was not more effective than N-acetylcysteine, and the combination of GS-459679 and N-acetylcysteine exhibited similar efficacy as N-acetylcysteine monotherapy, suggesting that GS-459769 and N-acetylcysteine affect the same pathway. Importantly, inhibition of ASK1 did not impair liver regeneration as indicated by PCNA staining. In conclusion, the ASK1 inhibitor GS-459679 protected against APAP toxicity by attenuating JNK activation and oxidant stress in mice and may have therapeutic potential for APAP overdose patients.
代谢活化和氧化应激是对乙酰氨基酚(APAP)肝毒性病理生理学中的关键事件。由蛋白质加合物形成引发的初始线粒体氧化应激通过c-jun氨基末端激酶(JNK)放大,导致线粒体功能障碍并最终导致细胞坏死。凋亡信号调节激酶1(ASK1)被认为是氧化应激与JNK激活之间的联系。本研究的目的是评估小分子ASK1抑制剂GS-459679在APAP肝毒性小鼠模型中的疗效和作用机制。在24小时观察期内,APAP(300mg/kg)导致广泛的谷胱甘肽耗竭、JNK激活并转位至线粒体、氧化应激和肝损伤,这可通过血浆ALT活性和坏死面积来表明。用30mg/kg的GS-459679预处理几乎完全阻止了JNK激活、氧化应激和损伤,而不影响APAP的代谢活化。为了评估GS-459679的治疗潜力,小鼠先用APAP处理,然后用抑制剂处理。在APAP给药1.5小时后给予GS-459679仍具有保护作用,这与JNK激活减少和p-JNK转位至线粒体平行。然而,GS-459679治疗并不比N-乙酰半胱氨酸更有效,并且GS-459679与N-乙酰半胱氨酸的联合使用显示出与N-乙酰半胱氨酸单药治疗相似的疗效,这表明GS-459769和N-乙酰半胱氨酸影响相同的途径。重要的是,如PCNA染色所示,抑制ASK1并不损害肝再生。总之,ASK1抑制剂GS-459679通过减轻小鼠的JNK激活和氧化应激来预防APAP毒性,并且可能对APAP过量患者具有治疗潜力。